XML 23 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Equity Financings and Warrants
6 Months Ended
Jun. 30, 2017
Equity [Abstract]  
Equity Financings and Warrants

(7) Equity Financings and Warrants

2017 Equity Financing

 

On January 11, 2017, the Company entered into a Capital on Demand TM Sales Agreement (the Sales Agreement) with JonesTrading Institutional Services LLC, as agent (JonesTrading), pursuant to which the Company may offer and sell, from time to time through JonesTrading, shares of the Company’s common stock, par value $0.001 per share (the Common Stock), having an aggregate offering price of up to $7.3 million (the Shares).  

Under the Sales Agreement, JonesTrading may sell the Shares by any method permitted by law and deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on or through The NASDAQ Capital Market, on any other existing trading market for the Common Stock or to or through a market maker. In addition, under the Sales Agreement, JonesTrading may sell the Shares by any other method permitted by law, including in negotiated transactions. The Company may instruct JonesTrading not to sell Shares if the sales cannot be effected at or above the price designated by the Company from time to time.

The Company is not obligated to make any sales of the Shares under the Sales Agreement. The offering of Shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by JonesTrading or the Company, as permitted therein.

The Company will pay JonesTrading a commission rate equal to 3.0% of the aggregate gross proceeds from each sale of Shares and have agreed to provide JonesTrading with customary indemnification and contribution rights. The Company will also reimburse JonesTrading for certain specified expenses in connection with entering into the Sales Agreement.

 

As of June 30, 2017, the Company has sold an aggregate of 1,019,282 shares of Common Stock pursuant to the terms of such Sales Agreement for aggregate gross proceeds of approximately $2.5 million.  Net proceeds received during the six months ended June 30, 2017 were approximately $2.1 million, including initial expenses for executing the “at the market offering” and commissions to the placement agent.  

See Note 10 for information regarding sales through this facility subsequent to June 30, 2017.

Warrants

Warrants to purchase shares of common stock were previously granted as part of various financing and business agreements.  All outstanding warrants were recorded in additional paid-in capital at their estimated fair market value at the date of grant using a Black-Scholes option-pricing model.

As of June 30, 2017, these warrants, by year of expiration, are summarized below:

 

Year of Expiration

 

Number

of Warrants

 

 

Weighted Average

Exercise Price

 

2017

 

 

24,124

 

 

$

17.89

 

2018

 

 

963,153

 

 

 

11.77

 

2019

 

 

224,323

 

 

 

15.73

 

2020

 

 

44,299

 

 

 

15.96

 

2022

 

 

2,401,233

 

 

 

6.10

 

 

 

 

3,657,132

 

 

$

8.38